The Science.
Receptor-level proof, not marketing claims.
Every Junsui Mirai active is documented in peer-reviewed literature. Four molecules. Four receptor pathways. Numerical endpoints with cohort sizes, follow-up windows, and DOIs you can verify.
Four molecules. Four honesty tiers. Zero borrowed glow.
We tell you which tier you're in.
Skin-booster science varies massively by ingredient. Rather than pretend every active is equally proven, we tier them honestly.
Decades of evidence
Clinically promising · rapidly growing
Mechanistically compelling · clinically young
Pick a pathway.
Each card opens a full monograph — mechanism diagram, molecular profile, pharmacology, and cited studies.
PDRN
ポリデオキシリボヌクレオチドSalmon-derived polydeoxyribonucleotide. The adenosine A2A pathway, weaponized.
GHK-Cu
銅ペプチドThe endogenous copper-carrier peptide. Genomic-level skin remodeling.
Hyaluronic Acid
ヒアルロン酸Cross-linked and free-form HA, engineered as a stratified hydration matrix.
Niacinamide
ナイアシンアミドThe barrier and pigment modulator. A NAD⁺ precursor with 50 years of clinical data.
Actives, compared.
Four molecules, four receptor targets, four onset curves. This matrix is the fastest way to understand why we built the arsenal the way we did.
| Active | Receptor / Target | MW | Depth | Primary action | Onset | Peak effect | Headline endpoint |
|---|---|---|---|---|---|---|---|
| PDRN | A2A adenosine receptor | 50 – 1,500 kDa | Mid-deep dermis | Tissue regeneration | 24 – 72h (VEGF / FGF-2) | 8 – 16 weeks | −47% scar volume |
| GHK-Cu | Lysyl oxidase · SOD2 · 4,192 genes | 340 Da (peptide) / 404 Da (complex) | Upper-mid dermis | Genomic reset · matrix remodel | Gene expression in 24h | 12 weeks | 31.2% age-genes reset |
| Hyaluronic Acid | CD44 · hydrogen bonding | 5 / 200 / 1,500 kDa stratified | Epidermis → deep dermis | Hydration · scaffold | Immediate (hours) | 4 – 8 weeks (cumulative) | +40% hydration |
| Niacinamide | NAD⁺ pool · PAR-2 · ceramide synthase | 122 Da | Full epidermis | Barrier · pigment · sebum | Barrier markers in 2 weeks | 8 – 12 weeks | −68% hyperpigmentation |
What's actually in the bottle.
Most brands hide the percentage. We list ours next to the clinical-grade benchmark and the typical OTC concentration so you can judge potency directly.
| Molecule | Junsui Mirai | Clinical-grade range | Typical OTC |
|---|---|---|---|
| PDRN | 2.0 mg/ml | 0.75 – 2.0 mg/ml | <0.1 mg/ml typical |
| GHK-Cu | 0.05% (500 µg/ml) | 0.05 – 0.2% | 0.01 – 0.05% |
| Hyaluronic Acid | 1.2% triple-MW | 20 – 24 mg/ml filler | 0.1 – 2% single-MW |
| Niacinamide | 4.0% | 5% | 2 – 10% |
How we stack against the field.
No vague "premium" claims. Specifications next to named competitors, with their disclosed concentrations or — where they refuse to disclose — that fact stated.
Saisei — 2.0 mg/ml salmon PDRN · tri-pin intradermal cap · 5 vials per box
Hari — 0.05% GHK-Cu (500 µg/ml) · pH 6.8 · BDDE-free HA carrier
Mizu — 1.2% total · 5 / 200 / 1,500 kDa triple-MW blend · BDDE-free crosslink
Mugen — PDRN + GHK-Cu + HA + Niacinamide in a single stabilised matrix
The arsenal, in numbers.
Mean treatment effects from the peer-reviewed studies cited on the molecule pages. Not best-responder anecdotes.
A working protocol.
The four actives are designed to layer. Below is the cadence we built the products around — Saisei once every 6 weeks for 5 – 6 sessions, then once every 3 months for maintenance, scaffolded daily by Mizu and Hari.
| Phase | Action | Pharmacological rationale |
|---|---|---|
| Session 1 | Saisei (PDRN) intradermal via tri-pin | Seed A2A receptor activation, growth factor cascade |
| Between sessions | Mizu nightly + Hari every other AM | Hydration scaffold + copper-peptide gene modulation between PDRN deposits |
| Sessions 2 – 6 | Repeat Saisei once every 6 weeks | 5 – 6 sessions total · sustain VEGF / FGF-2 remodelling cycle |
| Maintenance | Saisei once every 3 months + Mugen 3× weekly | Lock in dermal remodelling; Mugen covers all four pathways daily |
How we cite.
Every endpoint on this site is sourced from a PubMed-indexed journal. We do not cite influencer reviews, white papers, or in-house data as evidence.
Each study lists a DOI or PMID. Click through to confirm cohort size, control arm, and reported effect size.
We report mean treatment effects vs. control, not best-responder anecdotes. If a study shows 47%, we write 47% — not 'up to 90%'.
Terms used on this site.
- A2A receptor
- G-protein coupled adenosine receptor; primary docking site for PDRN nucleotides on fibroblasts.
- CD44
- Cell-surface receptor that binds hyaluronic acid fragments and triggers barrier-lipid synthesis.
- Lysyl oxidase (LOX)
- Copper-dependent enzyme that crosslinks collagen and elastin fibres.
- NAD⁺
- Nicotinamide adenine dinucleotide — central redox cofactor; biosynthesised from niacinamide.
- ECCA grading
- Échelle d'évaluation clinique des cicatrices d'acné — validated atrophic-scar volume score.
- MMP-1
- Matrix metalloproteinase-1; the collagenase enzyme upregulated by UV exposure.
- PAR-2
- Protease-activated receptor 2 on keratinocytes; mediates melanosome uptake. Blocked by niacinamide.
- BDDE
- 1,4-butanediol diglycidyl ether — common HA crosslinker. Junsui Mirai is BDDE-free.
Regenerative aesthetics. Longevity.
Japanese beauty philosophy. Biotech skincare.
Four currents meeting in one quiet object.
Not "look younger." Supporting the biological environment of resilient skin — articulated where most aesthetics brands choose marketing instead.